Product Name: CD1a Antibody [66IIC7]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P, WB
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 1-2 ug/mlImmunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RT (1)Optimal dilution of the CD1a antibody should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Human thymocytes were used as the immunogen for the CD1a antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 1025015-40-0
Product: GK921
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: T-cell surface glycoprotein CD1a, T-cell surface antigen T6/Leu-6, hTa1 thymocyte antigen, CD1a, CD1A
Accession NO.:
Protein Ino:
Official Symbol: CD1A
Geneid: 909
Background: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).
PubMed ID:http://aac.asm.org/content/34/3/402.abstract
